Empagliflozin

Adults with heart failure with reduced ejection fraction derived similar benefits with empagliflozin regardless of other disease-modifying heart failure therapies prescribed at baseline, post hoc analysis of the EMPEROR-Reduced trial show.

Empagliflozin (Jardiance, Boehringer Ingelheim/Eli Lilly) vs. placebo in patients hospitalized with acute HF.

In this video, Nancy K. Sweitzer, MD, PhD, discussed results from the EMPULSE trial presented at this year’s American Heart Association Scientific Sessions.

In a new analysis of the EMPEROR-Preserved trial, the SGLT2 inhibitor empagliflozin reduced CV death or HF hospitalization by 17% among those with a left ventricular ejection fraction of at least 50%.

In the EMPULSE trial, adults hospitalized with acute HF who received the SGLT2 inhibitor empagliflozin were 36% more likely than those on placebo to have clinical benefit at 90 days, including prevention of death and readmissions.

The FDA has accepted a supplemental new drug application and granted priority review of empagliflozin for the reduction of CV death and HF hospitalization for adults with HF, regardless of left ventricular ejection fraction.

Patients with chronic kidney disease and heart failure who took the sodium glucose co-transporter 2 inhibitor empagliflozin saw a stabilization of ejection fraction and a slowing in eGFR decline, according to trial results presented here.

Compared with just a few years ago, medical treatment options for HF with preserved ejection fraction have expanded greatly, culminating in the first useful new agent for the HFpEF population.

Empagliflozin reduced risk for heart failure hospitalization similarly in people with and without type 2 diabetes and delayed the need for insulin initiation in those with diabetes or prediabetes, data from EMPEROR-Preserved show.

The American Heart Association Scientific Sessions will be a fully virtual event held Nov. 13-15, 2021, and will feature seven late-breaking science sessions over 3 days.